26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
10 October 2024 - BasileaStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this yearIsavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba®.read more >>
24 September 2024 - BasileaBasilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasisInvasive Candida infections are life-threatening complications for many hospitalized patients and associated with high mortality, and fosmanogepix offers a potential…read more >>
24 September 2024 - BioVersys AGBioVersys: Nature Reviews Highlights Significant Successes of Antibiotic Collaboration and Calls for Sustainable R&D Funding SchemesThe continued innovation for developing new antibiotics fighting AMR is crucial for modern medicine, in high- and low-income countries. There…read more >>
23 September 2024 - QureTech Bio ABQureTech Bio announces prestigious investment from KempestiftelsernaWith this financial support, QureTech Bio will be able to accelerate its research and development efforts of novel antibiotic treatments…read more >>
20 September 2024 - AdjuTec Pharma ASAdjuTec Pharma Starts First-In-Human Clinical Trial of APC148 in Healthy VolunteersHaving reached this phase 1 study is an exciting milestone for Adjutec and will give us important safety data and…read more >>
19 September 2024 - BasileaBasilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial fundingBasilea has been working with BARDA since 2013. In continuing this partnership through an OTA, we will be leveraging our…read more >>
12 October 2023REVIVE Webinar – Market interventions to improve access to antibiotics for resistant infectionsThis webinar will invite experts in market shaping, describe how market shaping interventions in other areas may be applied to…read more >>
27 September 2023GARDP Webinar: Antibiotic shortages: causes, consequences, and solutionsThe Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that…read more >>
20 September 2023ChinaBio® Partnering Forum 2023ChinaBio® Partnering Forum is the largest and most productive life science partnering conference in China.read more >>
20 September 2023REVIVE Webinar – Clinical trials platforms for new and neglected antimicrobialsThe Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization, registered under the legal name GARDP Foundation,…read more >>
07 September 2023World AMR CongressSince 2015, the World Anti-Microbial Resistance Congress has been the go-to conference globally for all stakeholders in the AMR space…read more >>
05 September 2023REVIVE Webinar – Starting an antibacterial drug discovery screening programmeThe Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization, registered under the legal name GARDP Foundation,…read more >>
24 August 2023REVIVE Webinar – Antimicrobial drug discovery: SAR optimization and QSARThe Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization, registered under the legal name GARDP Foundation,…read more >>
21 June 2023AMR – Antimicrobial Resistance ConnectDriving innovation, investment, and actionable policy to combat the silent pandemicread more >>
07 June 2023GARDP Webinar: Project management in antimicrobial drug R&DThe Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that…read more >>
